Despite major advances in oncology, drug resistance remains one of the principal obstacles to achieving durable responses and cure in cancer patients. Both ...

The Government has clarified that all oncology medicines are covered under the Drugs (Prices Control) Order, 2013 (DPCO, 2013 ...

Drug resistance continues to limit the long-term benefit of many targeted therapies and chemotherapies against cancer. While “classical” small-molecule ...

Researchers say study results provide a clear rationale for developing therapies that target LCN2 in lung cancer patients.

From antibiotic resistance to emerging viral threats, the global demand for new medicines is intensifying, yet traditional drug discovery pipelines remain slow and expensive. A new scientific review ...

In a follow-up to the customs duty relief on essential medicines, the National Pharmaceutical Pricing Authority (NPPA) has directed manufacturers and marketing companies of the ...

The National Cancer Institute, the federal research agency charged with leading the war against the nation's second-largest ...

The National Cancer Institute, the federal research agency charged with leading the war against the nation’s second-largest killer, is studying ivermectin as a potential cancer treatment, according to ...

Seventy-five percent of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) who were treated with the antibody ...

Drug repurposing analyses show that citalopram exerts anti-tumor effects by targeting C5aR1 on tumor-associated macrophages to enhance phagocytosis and CD8+ T cell immunity.

This new article publication from Acta Pharmaceutica Sinica B, discusses the deep learning-based discovery of tetrahydrocarbazoles as broad-spectrum antitumor agents and click-activated strategy for ...